Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Jul;45(5):1072-1082.
doi: 10.1002/jpen.1983. Epub 2020 Aug 25.

Postsurgical Intestinal Rehabilitation Using Semisynthetic Glucagon-Like Peptide-2 Analogue (sGLP-2) at a Referral Center: Can Patients Achieve Parenteral Nutrition and sGLP-2 Independency?

Hector Solar  1   2 , Mariana Doeyo  1   2 , Mariana Ortega  1   2 , Silvia De Barrio  3 , Estela Olano  4 , Eduardo Moreira  4 , Martin Buncuga  5 , Alejandra Manzur  6 , Adriana Crivelli  1   2 , Gabriel Gondolesi  1   2
Affiliations
Observational Study

Postsurgical Intestinal Rehabilitation Using Semisynthetic Glucagon-Like Peptide-2 Analogue (sGLP-2) at a Referral Center: Can Patients Achieve Parenteral Nutrition and sGLP-2 Independency?

Hector Solar et al. JPEN J Parenter Enteral Nutr. 2021 Jul.

Abstract

Background: Teduglutide, a semisynthetic analogue of glucagon-like peptide-2 (sGLP-2), increases intestinal absorption of fluids and nutrients, reducing the need for parenteral nutrition (PN). This report aims to describe our experience with sGLP-2 in a cohort of adult patients with short-bowel syndrome.

Methods: This is a prospective observational study on adult patients initially evaluated in our specialized intestinal rehabilitation program that received sGLP-2 from June 2014 to March 2020.

Results: Autologous gastrointestinal reconstruction surgery (AGIRS) was performed in 108 patients; 68.5% (74 of 108) achieved intestinal sufficiency with standard medical therapy. Seventeen patients were treated with sGLP-2; 66.5% (8 of 12) received treatment for a mean time of 25.8 weeks (3.4-54.0) and could suspend PN. One patient reinitiated treatment due to renal lithiasis and acute renal failure. Currently, 7 of 12 patients (53.8%) continue without PN for a mean time of 165.6 weeks. Volume, energy, and days of PN were reduced in all patients. No serious adverse events were registered. Four of 7 patients (57.1%) who discontinued PN could also discontinue sGLP-2. Therefore, the use of sGLP-2 increased the overall success rate of PN independency after AGIRS to 76% (82 of 108).

Conclusion: This study confirmed that sGLP-2 should be considered as part of the standard therapy for postsurgical medical rehabilitation treatment in patients with chronic intestinal failure. We add to the current knowledge that some patients can discontinue both PN and sGLP-2 in the long term, achieving complete recovery of their quality of life.

Keywords: glp2; home nutrition support; intestinal failure; parenteral nutrition; rehabilitation; short bowel syndrome; surgery; teduglutide.

PubMed Disclaimer

References

    1. Pironi L, Arends J, Baxter J, et al. ESPEN endorsed recommendations. Definition and classification or intestinal failure in adults. Clin Nutr 2015;34(2):171-180.
    1. Pironi L. Definitions of intestinal failure and the short bowel syndrome. Best Pract Res Clin Gastroenterol 2016;30(2):173-185
    1. Pironi L. Revised ESPEN clinical classification of chronic intestinal failure: from 16 to 8 categories. JPEN J Parenter Enteral Nutr. 2017;41(6):911-911.
    1. Messing B, Crenn, P, Beau P, Boutron-Ruault MC, Rambaud JC, Matuchansky C. Long-term survival and parenteral nutrition dependence in adult patients with the short bowel syndrome. Gastroenterology. 1999;117(5):1043-1050.
    1. Amiot A, Messing B, Corcos O, Panis Y, Joly F. Determinants of home parenteral nutrition dependence and survival of 268 patients with non-malignant short bowel syndrome. Clin Nutr. 2013;32(3):368-374.

Publication types

Substances

LinkOut - more resources